|1.||Herholz, Karl: 2 articles (12/2014 - 01/2002)|
|2.||Hsu, Charlie Chia-Tsong: 1 article (11/2015)|
|3.||Singh, Dalveer: 1 article (11/2015)|
|4.||Lloyd, Jim: 1 article (12/2014)|
|5.||Bamford, Claire: 1 article (12/2014)|
|6.||Donaldson, Cam: 1 article (12/2014)|
|7.||Williams, David: 1 article (12/2014)|
|8.||Davison, Christopher: 1 article (12/2014)|
|9.||Barnett, Nicky: 1 article (12/2014)|
|10.||O'Brien, John T: 1 article (12/2014)|
|1.||Phantom Limb (Phantom Limbs)
09/01/1998 - "This study examined the change of regional cerebral blood flow using technetium-99m hexamethylpropyleneamine oxime-single photon emission computerized tomography, which was arranged at the time of severe phantom limb discomfort and after the discomfort subsided or was completely relieved. "
|2.||Schizophrenia (Dementia Praecox)
06/14/1997 - "24 never-treated patients with acute schizophrenia were examined with hexamethylpropyleneamine-oxime brain SPECT and assessed psychopathologically according to the positive and negative syndrome scale; they were studied again after neuroleptic treatment and psychopathological remission. "
08/01/2012 - "The clinical performance of the Duke Endocarditis Service criteria to establish the diagnosis of infectious endocarditis (IE) can be improved through functional imaging procedures such as radiolabeled leukocytes ((99m)Tc-hexamethylpropyleneamine oxime [HMPAO]-labeled white blood cells [WBC]). "
06/01/1990 - "We investigated 32 patients with completed ischemic stroke less than or equal to 6 hours after the onset of symptoms by means of computed tomography, cerebral angiography, and technetium-99m-labeled hexamethylpropyleneamine oxime single-photon emission computed tomography to study cerebral blood flow. "
06/01/2012 - "Here, a pseudo-continuous ASL technique (pCASL) was evaluated against (99m)Tc-D, L-hexamethylpropyleneamine oxime ((99m)Tc-HMPAO) autoradiography in a rat stroke model. "
05/01/2006 - "Correlation of magnetic resonance imaging findings with hexamethylpropyleneamine oxime brain single photon emission computed tomography in ischemic stroke patients in the subacute stage."
05/01/2002 - "Five stroke patients and 16 normal controls underwent Tc-99m hexamethylpropyleneamine-oxime brain SPECT and 1H MRSI at 4.1 T. "
10/01/2000 - "The relation was studied retrospectively between initial regional cerebral blood flow (rCBF) quantitatively measured by technetium-99m-labelled hexamethylpropyleneamine oxime ((99m)Tc-HMPAO) SPECT and final clinical and radiological outcome in 20 patients who presented hemispheric ischaemic stroke and were treated conservatively or received early recanalisation by local intra-arterial thrombolysis. "
|5.||Alzheimer Disease (Alzheimer's Disease)
03/01/2005 - "To prospectively determine if pulsed arterial spin-labeling perfusion magnetic resonance (MR) imaging depicts regional cerebral hypoperfusion in subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI), compared with perfusion in cognitively normal (CN) subjects, that is consistent with results of fluorodeoxyglucose (FDG) positron emission tomography (PET) and hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) studies of similar populations. "
09/23/2011 - "These patients were assessed using the Neuropsychiatric Inventory, the Alzheimer's disease assessment scale, cognitive subscale and perfusion SPECT performed with 99Tc(m) hexamethylpropyleneamine oxime. "
06/01/1994 - "The value of hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) as a diagnostic test for Alzheimer's disease (AD) was assessed in 44 patients attending a Memory Clinic. "
09/01/1988 - "Regional cerebral perfusion was evaluated by single photon emission computed tomography (SPECT) using technetium-99m hexamethylpropyleneamine oxime ([99mTc]HM-PAO) in sixteen patients with Alzheimer's disease (AD) in early clinical phase and in 16 healthy elderly controls. "
01/01/2002 - "Hexamethylpropyleneamine oxime (HMPAO) SPECT and 18F-FDG PET depict similar aspects of perfusion and metabolic abnormalities in Alzheimer's disease (AD), but the correspondence between them is not known in detail. "
|1.||Technetium (Technetium 99m)
|2.||Hanks Balanced Salt Solution
|3.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|4.||Technetium Tc 99m Exametazime (Ceretec)
|6.||Inosine Monophosphate (IMP)
|9.||Deoxyglucose (2 Deoxy D glucose)